Skip to Content

Patients with malignant pleural mesothelioma continue to benefit from immunotherapy combination

CheckMate 743 study confirms that combination treatment with nivolumab and ipilimumab prolongs overall survival in patients with unresectable malignant pleural mesothelioma

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top